Bicycle Therapeutics (BCYC) Competitors $13.34 -0.25 (-1.84%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BCYC vs. OGN, ADMA, SRRK, ALVO, RARE, VRNA, BHVN, CRNX, ACLX, and APLSShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Organon & Co. (OGN), ADMA Biologics (ADMA), Scholar Rock (SRRK), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), Verona Pharma (VRNA), Biohaven (BHVN), Crinetics Pharmaceuticals (CRNX), Arcellx (ACLX), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Organon & Co. ADMA Biologics Scholar Rock Alvotech Ultragenyx Pharmaceutical Verona Pharma Biohaven Crinetics Pharmaceuticals Arcellx Apellis Pharmaceuticals Organon & Co. (NYSE:OGN) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Is OGN or BCYC more profitable? Organon & Co. has a net margin of 20.30% compared to Bicycle Therapeutics' net margin of -450.64%. Organon & Co.'s return on equity of 644.70% beat Bicycle Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.20.30% 644.70% 8.12% Bicycle Therapeutics -450.64%-27.35%-20.81% Do institutionals & insiders hold more shares of OGN or BCYC? 77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 1.4% of Organon & Co. shares are held by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable valuation and earnings, OGN or BCYC? Organon & Co. has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.26B0.65$1.02B$5.043.13Bicycle Therapeutics$26.98M34.14-$180.66M-$3.29-4.05 Which has more volatility and risk, OGN or BCYC? Organon & Co. has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Does the MarketBeat Community favor OGN or BCYC? Bicycle Therapeutics received 121 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 70.41% of users gave Bicycle Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes1733.33% Underperform Votes3466.67% Bicycle TherapeuticsOutperform Votes13870.41% Underperform Votes5829.59% Do analysts rate OGN or BCYC? Organon & Co. presently has a consensus target price of $21.33, suggesting a potential upside of 35.32%. Bicycle Therapeutics has a consensus target price of $34.50, suggesting a potential upside of 158.62%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40Bicycle Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media refer more to OGN or BCYC? In the previous week, Bicycle Therapeutics had 9 more articles in the media than Organon & Co.. MarketBeat recorded 18 mentions for Bicycle Therapeutics and 9 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.09 beat Bicycle Therapeutics' score of 0.46 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBicycle Therapeutics beats Organon & Co. on 10 of the 19 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$919M$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-4.059.5287.9117.30Price / Sales34.14313.591,258.3378.69Price / CashN/A61.4443.8235.97Price / Book1.086.055.324.79Net Income-$180.66M$154.90M$122.78M$225.07M7 Day Performance0.23%-1.71%-0.19%1.52%1 Month Performance-12.87%2.71%3.73%4.69%1 Year Performance-24.80%2.79%27.32%20.91% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.2881 of 5 stars$13.34-1.8%$34.50+158.6%-26.8%$919M$26.98M-4.05240Short Interest ↑Analyst RevisionGap UpOGNOrganon & Co.4.8042 of 5 stars$15.57-1.8%$21.33+37.0%-0.8%$4.01B$6.41B3.0910,000Analyst UpgradePositive NewsADMAADMA Biologics3.9401 of 5 stars$16.89-9.0%$21.25+25.8%+224.9%$3.99B$382.81M60.32530Short Interest ↑Analyst RevisionSRRKScholar Rock3.1312 of 5 stars$42.64+5.3%$40.43-5.2%+176.7%$3.99B$33.19M-18.14140Positive NewsALVOAlvotech2.7377 of 5 stars$13.20-2.4%$18.00+36.4%+7.4%$3.98B$391.87M-7.141,026RAREUltragenyx Pharmaceutical4.5986 of 5 stars$42.76+1.6%$92.29+115.8%-7.9%$3.95B$522.75M-6.611,276Analyst RevisionNews CoverageGap DownVRNAVerona Pharma2.0512 of 5 stars$46.83+3.6%$50.57+8.0%+201.0%$3.77B$5.62M-24.3930BHVNBiohaven2.4245 of 5 stars$37.00+0.8%$63.00+70.3%-13.6%$3.74B$462.51M-3.96239Short Interest ↑Gap UpCRNXCrinetics Pharmaceuticals3.7194 of 5 stars$38.97-4.0%$74.40+90.9%+1.5%$3.61B$1.04M-10.45210Short Interest ↑ACLXArcellx3.1719 of 5 stars$66.44-3.8%$105.93+59.4%+21.2%$3.59B$155.82M-93.58130Short Interest ↑APLSApellis Pharmaceuticals4.4036 of 5 stars$28.75+4.8%$46.65+62.3%-54.6%$3.58B$715.22M-14.16770Analyst ForecastInsider TradeShort Interest ↑Gap Up Related Companies and Tools Related Companies Organon & Co. Competitors ADMA Biologics Competitors Scholar Rock Competitors Alvotech Competitors Ultragenyx Pharmaceutical Competitors Verona Pharma Competitors Biohaven Competitors Crinetics Pharmaceuticals Competitors Arcellx Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCYC) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
